Cancer
Avastin study in ovarian cancer meets primary endpoint
February 25, 2010Research and Development Cancer, avastin, ovarian
Preliminary results from a trial of Roche’s Avastin in advanced ovarian cancer suggest that the drug lengthens progression-free survival when …
Pfizer, Lilly and Merck partner for cancer research
February 23, 2010Research and Development Asia, Cancer, developing world, em, emerging markets
Three pharma companies have formed a not-for-profit organisation, the Asian Cancer Research Group (ACRG), to boost work on treating common …
Boehringer targets ‘genome guardian’ protein for cancer collaboration
January 19, 2010Research and Development Boehringer, Cancer, Priaxon, genome
Boehringer Ingelheim has signed a worldwide deal with Munich-based pharma firm Priaxon to find novel treatments for cancer. The firms …
Pfizer signs ‘personalised’ cancer collaboration
January 15, 2010Research and Development Cancer, Debiopharm, Pfizer, melanoma, skin cancer, tremelimumab
Pfizer is to co-develop its monoclonal antibody treatment for advanced melanoma with Swiss company Debiopharm. The companies will conduct phase …
Boehringer’s ovarian cancer drug enters phase III
December 18, 2009Research and Development, Sales and Marketing Boehringer, Cancer, ovarian
Boehringer Ingelheim has started a new phase III trial for its investigational cancer drug BIBF 1120. The LUME-Ovar-1 programme will …
UK faces north/south divide on cancer
December 1, 2009Sales and Marketing Cancer, NHS
There is a marked north/south divide when it comes to cancer patients’ chances of recovery, according to new statistics. The …
GSK kidney cancer drug approved in US
October 20, 2009Research and Development, Sales and Marketing Cancer, GSK, rcc
GlaxoSmithKline’s Votrient has been approved in the US by the FDA to treat the most common form of kidney cancer.This …
FDA revises cancer vaccine guidance
October 12, 2009Sales and Marketing Cancer, US, reg, vacccine
There are concerns that draft guidance from the US Food and Drug Administration, which will recommend that cancer vaccine trials …
AZ signs biomarker research deal
October 5, 2009Research and Development AZ, Cancer
A deal between AstraZeneca and Cancer Research UK is set to expand biomarker research into how new drugs behave in …
Nexavar shows promise in breast cancer
September 24, 2009Sales and Marketing Cancer, Nexavar, breast cancer
Bayer’s Nexavar has been shown to significantly extend progression-free survival in patients with advanced breast cancer in a new phase …
Merck’s osteoporosis candidate shows some promise in trials
September 16, 2009Research and Development, Sales and Marketing Cancer, Merck
Merck & Co's investigational cathepsin K inhibitor odanacatib has shown some promise in a trial to treat osteoporosis in postmenopausal …
New cancer cases set to hit 17 million by 2020
September 2, 2009Research and Development, Sales and Marketing Cancer, healthcare
The next ten years will see a 30% leap in the number of new cancer cases across the world, according …
Off-label rules for cancer need to be clarified
August 18, 2009Research and Development, Sales and Marketing Cancer, NHS, off label
A new report is pressing for the off label prescribing of drugs to be made clearer and more fair for …
Afinitor approved in EU
August 6, 2009Research and Development, Sales and Marketing Afinitor, Cancer, Europe, Novartis
Novartis’ new kidney cancer drug Afinitor (everolimus) has been approved in the EU for use when products such as Sutent …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
